Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden

Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden

Abstract Background Voriconazole is well established as standard treatment for invasive aspergillosis (IA). In 2017, isavuconazole, a new antifungal from the azole class, with a broader pathogen spectrum, was introduced in Sweden. A model has therefore been developed to compare the cost-effectivenes...

Full description

Bibliographic Details
Main Authors: Lefteris Floros, Daniel Kuessner, Jan Posthumus, Emma Bagshaw, Jan Sjölin
Format: Article
Language:English
Published: BMC 2019-02-01
Series:BMC Infectious Diseases
Subjects:
Isavuconazole
Voriconazole
Cost-effectiveness
Invasive aspergillosis
Mucormycosis
Sweden
Online Access:http://link.springer.com/article/10.1186/s12879-019-3683-2

Internet

http://link.springer.com/article/10.1186/s12879-019-3683-2

Similar Items